AstraZeneca continues to build out its presence in China with new COPD drug manufacturing site
AstraZeneca has been growing its presence in China over the past several years, and the pharma’s latest venture in the country will see it establish a manufacturing process for COPD treatments.
According to a press release, translated from Chinese, AstraZeneca officially announced it will expand its investment in China and plans to spend some cash to construct a production and supply base as well, as a regional headquarters in the port city of Qingdao, Shandong in eastern China. Qingdao will also be home to an innovation center focused on rare diseases, a life science innovation park and an industrial fund.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.